Brief Report

iMedPub Journals
http://www.imedpub.com/

Chronic Obstructive Pulmonary Disease: Open Access
ISSN 2572-5548

2025
Vol.10 No.01: 02

Crosstalk between Lungs, Cardiovascular System and Metabolism

Dodson Batalov*

Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK

*Corresponding author: Dodson Batalov, Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK; E-mail: batalovdodson@os.uk

Rec date: January 06, 2025; **Acc date:** January 08, 2025; **Pub date:** January 31, 2025

Citation: Batalov D. (2025) Crosstalk between Lungs, Cardiovascular System and Metabolism. Chron Obstruct Pulmon Dis 10.01: 02.

Introduction

The human body functions as an integrated network where organs do not operate in isolation but rather engage in continuous dialogue through biochemical, hormonal, and mechanical signals. Among these intricate interactions, the crosstalk between the lungs, cardiovascular system, metabolic pathways is particularly significant because of its direct implications for health and disease. The cardiovascular system ensures efficient delivery of oxygen and nutrients to peripheral tissues while also carrying waste products back to the lungs, kidneys, liver for clearance. At the same time, metabolism not only dictates the body's energy balance but also generates molecular signals that directly affect lung and cardiovascular physiology. Disruption in this interconnected network gives rise to complex disease phenotypes such as chronic obstructive pulmonary disease, pulmonary hypertension, metabolic syndrome, diabetes, and heart failure. Research has shifted from examining these organ systems separately to recognizing their dynamic interplay, revealing novel insights into pathophysiology and opportunities for integrated therapeutic strategies [1].

Description

The lungs are central to systemic oxygen homeostasis, and their role extends far beyond gas exchange. They act as endocrine organs, releasing bioactive molecules such as prostaglandins, nitric oxide, and endothelin that influence vascular tone and systemic circulation. The cardiovascular system, in turn, adapts to changes in pulmonary function. Hypoxia resulting from impaired lung function triggers pulmonary vasoconstriction, increasing the workload on the right ventricle and predisposing individuals to pulmonary hypertension. This hemodynamic burden translates into structural remodeling of the heart, culminating in cor pulmonale. Metabolic disturbances exacerbate pulmonary dysfunction by promoting systemic inflammation, oxidative stress, and endothelial injury [2].

Cardiopulmonary crosstalk is especially evident in conditions of chronic hypoxia. In diseases such as COPD, interstitial lung disease, or sleep apnea, reduced oxygenation activates hypoxia-inducible factors (HIFs), transcriptional regulators that orchestrate adaptive responses in multiple tissues. In the lungs, HIF activation promotes angiogenesis, glycolysis, and erythropoiesis; in the cardiovascular system, it stimulates vascular remodeling and increases sympathetic drive, leading to hypertension and arrhythmias. Metabolically, chronic hypoxia shifts cellular energy production from oxidative phosphorylation toward glycolysis, even in the presence of oxygen—a phenomenon reminiscent of the Warburg effect seen in cancer. This metabolic reprogramming, while adaptive in the short term, contributes to insulin resistance, muscle wasting, and impaired mitochondrial function in the long run. Thus, hypoxia serves as a unifying signal that simultaneously reshapes lung, heart, and metabolic physiology, explaining the clustering of comorbidities in patients with respiratory disease [3,4].

Systemic inflammation represents another major pathway of interaction between the lungs, cardiovascular system, and metabolism. Chronic inflammatory states, whether triggered by cigarette smoke, obesity, or hyperglycemia, lead to the release of pro-inflammatory cytokines such as TNF-α, IL-6, and CRP. These mediators act on endothelial cells, impairing nitric oxide bioavailability and promoting vascular stiffness, which in turn elevates blood pressure and increases the risk of atherosclerosis. The inflamed lung, through spillover of cytokines into systemic circulation, thus accelerates cardiovascular disease. Similarly, adipose tissue dysfunction in obesity generates adipokines such as leptin, resistin, and adiponectin, which modulate pulmonary immune responses and vascular reactivity. The convergence of these inflammatory pathways amplifies risk, leading to overlapping clinical entities such as the "cardiometabolic lung syndrome." Patients with metabolic syndrome are more prone to develop asthma, COPD, and pulmonary hypertension, while those with chronic respiratory disease often present with metabolic and cardiovascular complications, illustrating the bidirectional influence of systemic inflammation. The heart and lungs also interact through hemodynamic coupling. The pulmonary circulation is a low-pressure system designed to accommodate the entire cardiac output with minimal resistance [5].

Conclusion

The lungs, cardiovascular system, and metabolism are intricately interconnected through shared pathways involving oxygen transport, inflammation, hemodynamics, mitochondrial function, and endocrine signaling. Disruption of this crosstalk contributes to the clustering of chronic diseases such as COPD, heart failure, and metabolic syndrome, representing a major challenge to global health. Recognition of these interactions underscores the need for integrated research frameworks and therapeutic strategies that transcend traditional organ-based boundaries. By embracing a systems-level perspective, clinicians and scientists can better understand the complex interplay shaping disease progression and patient outcomes. Ultimately, targeting the lung-heart-metabolism axis offers a promising avenue toward more effective, personalized, and holistic healthcare interventions, with the potential to transform the management of some of the most prevalent and debilitating diseases of our time.

Acknowledgment

None.

Conflict of Interest

None.

REFERENCES

1. Hao Q, Dong BR (2015). Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 3: CD006895.

2. Mullish BH, Marchesi JR, McDonald JA, Pass DA, Masetti G, et al. (2021). Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: Should we be considering probiotics during viral pandemics?. Gut Microbes 13: 1900997.

3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382: 1708-1720.

4. Morrow LE, Kollef MH, Casale TB (2010). Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Care Med 182: 1058-1064.

5. Bell TJ, Brand OJ, Morgan DJ, Salek-Ardakani S, Jagger C, et al. (2019). Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis. Matrix Biol 80: 14-28.